Accéder au contenu
Merck

18F-FPRGD2 PET/CT imaging of integrin αvβ3 in renal carcinomas: correlation with histopathology.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2015-02-07)
Nadia Withofs, Nicolas Signolle, Joan Somja, Pierre Lovinfosse, Eugène Mutijima Nzaramba, Frédéric Mievis, Fabrice Giacomelli, David Waltregny, Didier Cataldo, Sanjiv S Gambhir, Roland Hustinx
RÉSUMÉ

This study aimed to correlate (18)F-FB-mini-PEG-E[c(RGDyK)](2) ((18)F-FPRGD2) uptake to integrin αvβ3 expression and angiogenesis in renal tumors. (18)F-FPRGD2 PET/CT was performed on 27 patients before surgical resection (median 4 d) of a renal mass. The (18)F-FPRGD2 uptake was compared with integrin αvβ3, CD31, CD105, and Ki-67 using immunohistochemistry; with placental growth factor and vascular endothelial growth factor receptors 1 and 2 using reverse transcription polymerase chain reaction; and with vascular endothelial growth factor A isoforms using enzyme-linked immunosorbent assay. Overall, (18)F-FPRGD2 uptake significantly correlated (P < 0.0001) with integrin αvβ3 expression in renal masses. However, it correlated only with integrin αvβ3-positive vessels in the group of papillary carcinomas whereas it correlated with integrin αvβ3 expression by tumor cells in the clear cell carcinoma group. (18)F-FPRGD2 uptake reflects the expression of integrin αvβ3 in renal tumors but represents angiogenesis only when tumor cells do not express the integrin.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anti-Integrin αVβ3 Antibody, clone LM609, biotin conjugated, clone LM609, Chemicon®, from mouse